CliffBio
small molecule

VYNDAMAX

TAFAMIDIS

Loss of exclusivityAugust 2035latest FDA-listed patent expiry
CompanyFOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC

Drug detail

Brand nameVYNDAMAX
Active ingredientTAFAMIDIS
Strength61MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2019
Marketing statusRX

Listed patents

PatentExpiresType
9770441August 2035substance, product
7214696December 2026use U-2524
7214695December 2026substance, product

Regulatory exclusivity

CodeExpires
ODE-237May 2026

More from FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.